AstraZeneca records 50% share of gross profits on sales of Beyfortus in major markets outside the United States and 25% of ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

Beyfortus made almost $600 million in its first full year on the market in 2023, even though it was held back by manufacturing capacity constraints, and AZ and Sanofi are predicting it will cross ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Aug 17, 2024 18:48 Sanofi Gets CDSCO Nod for Beyfortus in India - Prevention of RSV Sanofi India receives marketing authorization for Beyfortus, a treatment for preventing Respiratory Syncytial Virus ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

Shortly after Amgen unveiled its $1.9 billion alliance with Generate Biomedicines aimed initially at five drug molecules, Sanofi has announced a big expansion of its longstanding partnership with ...

Sanofi India Limited (Previously known as Aventis Pharma Limited) was incorporated in May 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 2012. The ...

Sanofi Consumer Healthcare India Limited was incorporated on May 10 2023 pursuant to a Certificate of Incorporation issued by the Registrar of Companies Central Registration Centre. Pursuant to the ...